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Abstract 
Latent tuberculosis infection (LTBI) is characterized by the presence of immune responses to 
previously acquired Mycobacterium tuberculosis infection without clinical evidence of active 
tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization on 
a public health approach to manage LTBI in high risk individuals in countries with high or middle upper 
income and TB incidence of < 100/100,000 per year. The guidelines strongly recommend systematic 
testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, 
patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients 
preparing for organ or haematological  transplantation, and patients with silicosis. In prisoners, health-
care workers, immigrants from high TB burden countries, homeless persons and illicit drug users, 
systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology 
and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin 
skin testing could be used to test for LTBI. Chest radiography can be done before LTBI treatment to 
rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 
12 week rifapentine plus isoniazid; 3–4 month isoniazid plus rifampicin; or 3–4 month rifampicin alone.  
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Introduction  
Latent tuberculosis infection (LTBI) is characterized by the presence of immune responses to 
Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB) [1, 2]. One 
third of the world’s population is estimated to be infected with Mycobacterium tuberculosis [3]. The 
vast majority of infected persons have no signs or symptoms of TB disease and are not infectious, but 
they are at risk for developing active TB disease and becoming infectious [3]. The lifetime risk of 
reactivation TB for a person with documented LTBI is estimated to be 5–15%, with the majority 
developing TB disease within the first five years after initial infection [4]. However, the likelihood of 
progression of LTBI to active TB depends on bacterial, host, and environmental factors [3]. The 
reactivation of TB can be averted by preventive treatment. Currently available regimens for the 
treatment of LTBI have an efficacy ranging from 60% to 90%, the protection of which can last up to 19 
years [5]. The potential benefit of treatment needs to be carefully balanced against the risk of drug-
related adverse events. For infected individuals in population groups with a high risk of progression to 
active disease, the anticipated benefits are greater than the potential harms. It is thus important to 
identify which groups would benefit most. 
 
Guidelines were developed by the World Health Organization (WHO) in response to demand from 
several Member States for clear policy guidance on the management of LTBI. In addition, such 
guidelines will facilitate in achieving the ambitious targets of the WHO End TB Strategy [6]of a 90% 
reduction in TB incidence and a 95% reduction in TB deaths by 2035, and will contribute to the 
elimination of TB particularly in low TB incidence settings [7].  
This paper summarises the WHO guidelines on the management of LTBI, which provide guidance for 
addressing LTBI within a public health approach, and describes recommendations on who should be 
tested and treated for LTBI, what diagnostic algorithm should be used, as well as which treatment 
regimens should be adopted, in high and upper-middle income countries with a TB incidence less than 
100 per 100,000 population per year.  
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Methods  
The process and procedures for the development of the guidelines complied with the WHO Guidelines 
Review Committee requirements, including the establishment of a guidelines development panel, a 
systematic review of the evidence, and formulation of recommendations using a structured process 
[8]. The overall approach for the management of LTBI requires a comprehensive package of 
interventions that include: identifying populations at risk; adopting the appropriate diagnostic 
algorithm; delivering effective and safe treatment in a way that the majority of those who start 
treatment complete it with no or a minimal risk of adverse events; and developing a system for 
monitoring and evaluation (Figure 1). This package provided the framework for the development of 
the guidelines. Accordingly, key questions were formulated using the population, intervention, 
comparator, and outcomes (PICO) format to define the systematic reviews, and their relevant 
outcomes were selected and rated. From January to May 2014, a total of 14 systematic reviews were 
undertaken to inform the guidelines development. 
The quality of evidence and strength of recommendations were assessed using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) methodology when applicable 
[9-11]. In the GRADE process, the quality of a body of evidence (high, moderate, low or very low) is 
defined as the extent to which one can be confident that the reported estimates of effect (desirable 
or undesirable) available from the evidence are close to the actual effects of interest. The usefulness 
of an estimate of the effect (of the intervention) depends on the level of confidence in that estimate 
(i.e. the quality of evidence). The higher the quality of evidence, the more likely a strong 
recommendation can be made; however, the decision regarding the strength of the recommendation 
also depends on other factors, including the balance of desirable benefits and undesirable harms, the 
values and preferences of clients and health-care providers, as well as resource implications.  
 In accordance with GRADE, the recommendations in these guidelines were graded into two categories 
[12-14]. A strong recommendation was one for which the Panel was confident that the desirable 
effects of adherence to the recommendation outweighed the undesirable effects. This could be either 
in favor of or against an intervention. A conditional recommendation was one for which the Panel 
concluded that the desirable effects of adherence to the recommendation probably outweighed the 
undesirable effects, but the Panel was not confident about these trade‐offs. Reasons for not being 
confident included: absence of high-quality evidence (data to support the recommendation were 
scant); presence of imprecise estimates of benefits or harms (new evidence may result in changing 
the balance of risk to benefit); uncertainty or variation regarding how different individuals value the 
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outcomes (only applicable to a specific group, population or setting); small benefits and benefits that 
may not be worth the costs (including the costs of implementing the recommendation) [15]. 
The desirable effects that were considered included beneficial health outcomes (e.g. prevention and 
early diagnosis of TB, reduced TB-related morbidity and mortality, less transmission), less burden, and 
more cost savings; whereas undesirable effects included harms (adverse drug-related events), more 
burden, and more costs. Burdens considered included the demands of adhering to the 
recommendations that programmes, patients or caregivers (e.g. family) may have to bear, such as 
having to undergo more frequent tests, taking additional medications, or opting for a treatment that 
has a risk for toxicity.  
 
In principle, any country could benefit from systematic management of LTBI. However, these 
guidelines are primarily targeted to high-income or upper middle-income countries with an estimated 
TB incidence rate of less than 100 per 100 000 population per year. The Panel judged that these 
countries were most likely to benefit from programmatic management of LTBI due to their current TB 
epidemiology and resource availability. Therefore, data analysis of some of the systematic reviews 
considered a composite stratification of countries based on World Bank classification of income[16] 
and WHO estimate of TB incidence[17].  
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Results 
Target countries for the guidelines 
National TB Programmes or their equivalents in the ministries of health of high-income or upper 
middle-income countries with an estimated TB incidence rate of less than 100 per 100,000 population 
per year are the primary target audience for the guidelines presented here (Table 1). The guidelines 
are also relevant for other policy makers responsible for prison or social services, as well as 
immigration services (such as ministries of justice or correctional services, and ministries dealing with 
immigration). In addition to the guidelines described in this manuscript there are pertinent WHO 
guidelines on management of LTBI in people living with HIV[18] and child contacts below 5 years of 
age[19] which should be implemented in all countries. 
 
Identification of at risk populations  
Management of LTBI can prevent TB which is generated by progression from latent infection to disease.  
To assist in the identification of groups to prioritize for LTBI testing and treatment, we conducted a 
primary systematic review of the literature on the relative risk of progression from infection to disease 
in 24 pre-defined population groups. As evidence was very limited, two additional systematic reviews 
were conducted to measure the prevalence of LTBI, as well as incidence of active TB, relative to the 
general population, in those 24 groups.  
The first systematic review assessed the risk of progression from LTBI to active TB and was restricted 
to studies published from 1 January 2003 to 17 January 2014 in English, Spanish, French, and identified 
in MEDLINE. In addition, expert researchers were also contacted to identify any studies that met the 
inclusion criteria irrespective of date of publication. Eight individual studies provided evidence of an 
increased risk of progression from LTBI to active TB for the following risk groups: people living with 
HIV, adult contacts of TB cases, patients undergoing dialysis, underweight people, individuals with 
fibrotic radiologic lesions and Mantoux tuberculin skin test (TST) converters within the past two years.  
The second systematic review assessed the prevalence of Mycobacterium tuberculosis infection as 
determined either by TST or commercially available interferon-gamma release assays (IGRAs) and was 
restricted to studies published from 1 January 2003 to 17 January 2014 in English, Spanish, and French, 
and identified in MEDLINE. A total of 276 studies (with 299 entries) were included. Pooled relative 
risks were calculated by comparison of LTBI prevalence in risk groups (from individual studies) and the 
general population (using estimates derived from modelling)[20]. Considerable between-study 
heterogeneity was observed even after stratification for risk group. Nevertheless, an increased 
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prevalence of LTBI evidenced by positive TST or IGRA, compared to the general population, was 
reported in at least 65% of the identified studies for each of the following risk groups: adult and child 
contacts of persons with TB, prisoners, homeless people, elderly people, immigrants from high TB 
burden countries, and illicit drug users. 
The third systematic review was conducted to determine the pooled incidence rate ratio of active TB 
in the pre-defined risk groups compared with the general population. The search was restricted to 
studies published from 1 January 2004 to 31 March 2014 in English and identified through PUBMED.  
Evidence of increased risk of active TB was reported in the following risk groups: people living with 
HIV, adult and child contacts of a TB case, patients receiving dialysis, patients receiving anti-tumour 
necrosis factor (TNF)-alpha drugs, patients with silicosis, health-care workers (including students), 
immigrants from high TB burden countries, prisoners, the homeless, persons with cancer, diabetes 
mellitus, or harmful alcohol use, tobacco smokers and underweight people.  
Based on these findings the Panel issued the following recommendations (Box 1):  
 Systematic testing and treatment of LTBI should be performed in people living with HIV, adult and 
child contacts of pulmonary TB cases, persons initiating  anti-TNF-alpha treatment, receiving 
dialysis, preparing for organ or haematologic transplantation, or with silicosis. Either IGRA or 
Mantoux TST should be used to test for LTBI. (Strong recommendation, low to very low quality of 
evidence) 
 Systematic testing and treatment of LTBI should be considered for prisoners, health-care workers, 
immigrants from high TB burden countries, homeless persons and illicit drug users. Either IGRA or 
Mantoux TST should be used to test for LTBI. (Conditional recommendation, low to very low 
quality of evidence) 
 Systematic testing for LTBI is not recommended in people with diabetes, people with harmful 
alcohol use, tobacco smokers, and underweight people unless they are already included in the 
above recommendations. (Conditional recommendation, very low quality of evidence) 
The rationale for the Panel to make strong recommendations despite low to very low quality of 
evidence was based on the increased likelihood of progression to active TB disease, and that the 
benefits of treatment outweighed the potential harms in those at-risk population groups. Conditional 
recommendations were made primarily because of reservations on implementation issues, as well low 
quality of the evidence.  
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There was a paucity of data on the benefits and harms of systematic LTBI testing and treatment as 
well as doubts about its operational feasibility in diabetic patients, people with harmful alcohol use, 
tobacco smokers and underweight people. 
 
Excluding active TB and testing for LTBI 
Exclusion of active TB disease is an important initial step in the process of LTBI management. The 
fourth systematic review had been conducted in 2012 to determine the accuracy of symptoms and 
chest radiography screening for active pulmonary TB in HIV-negative persons and persons with 
unknown HIV status[21] as a screening rule for people living with HIV already exists[22].  The 
databases MEDLINE, EMBASE, LILIACS and Health Technology Assessment were searched from 1992 
to 2012, supplemented by a search of reference lists of relevant reviews and studies, websites of the 
WHO, and expert consultation for relevant studies and unpublished reports.  
The review identified 11 studies from general population surveys that provided data on screening with 
either symptoms or chest radiography or both[21]. Based on the review, a model was constructed to 
compare seven screening strategies to rule out active TB (Table 2).  The presence of any symptom 
suggestive of TB (i.e. any one of cough, haemoptysis, fever, night sweats, weight loss, chest pain, 
shortness of breath and fatigue) plus any abnormality on chest radiography offered the highest 
sensitivity and negative predictive value to rule out active TB.  
The fifth systematic review explored tests and clinical proxies that can best identify individuals most-
at-risk of progression to incident TB disease. While the systematic review did not identify any clinical 
parameter that would assist in the prediction of progression to active TB disease, 29 studies were 
assessed that provided information on the utility of IGRAs and TST in predicting the risk of TB. The 
main effect measure of interest was the risk ratio, comparing TB cumulative incidence following a 
positive test result versus a negative test result in individuals not receiving preventive therapy, or the 
incidence rate ratio in the few studies that reported the person-years of follow-up amongst persons 
with positive and negative tests.  
The main analysis was restricted to the eight studies that compared TST and IGRA to each other in the 
same study population (head-to-head comparison). The overall pooled risk ratio for test positives 
compared to test negatives for TST was 2.58 (95% CI: 1.72–3.88) and for IGRA 4.94 (95% CI: 1.79–
13.65). Similarly, the pooled incidence rate ratio in the three head-to-head studies with person-time 
data was 2.07 (95% CI: 1.38–3.11) for TST and 2.40 (95% CI: 1.26–4.60) for IGRA. In both analyses, the 
confidence intervals around the effect measures for the TST and IGRA were imprecise and largely 
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overlapped. There was insufficient data to provide evidence on predictive utility of the tests among 
specific high-risk groups. The added value of the tests over and above other clinical indicators of risk 
as well as their additive value when combining TST and IGRAs for diagnosis of LTBI could not be 
evaluated. 
Based on these findings the Panel issued the following recommendations: 
 Individuals should be asked about symptoms of TB before being tested for LTBI. Chest radiography 
can be done if efforts are intended also for active TB case finding. Individuals with TB symptoms 
or any radiological abnormality should be investigated further for active TB and other conditions. 
(Strong recommendation, very low quality of evidence) 
 Individuals with TB symptoms should be investigated further for active TB and other conditions. 
(Strong recommendation, very low quality of evidence).  
 Either TST or IGRA can be used to test for LTBI in high-income and upper middle-income countries 
with an estimated TB incidence of less than 100 per 100,000. (Strong recommendation, very low 
quality of evidence) 
 
Furthermore, the Panel maintained the existing WHO recommendation that IGRA should not replace 
TST in low-income and other middle-income countries. (Strong recommendation, very low quality of 
evidence) [23] 
 
Treatment options for LTBI 
The sixth systematic review was conducted to evaluate the efficacy and safety of treatment for LTBI 
[24]. Fifty three studies, all of which were randomized controlled trials and recorded at least one of 
the two pre-specified endpoints (preventing active TB, hepatotoxicity of Grade III or above), were 
included. Data was available for 15 treatment regimens, although relatively few direct comparisons 
were reported. In addition to standard meta-analysis, mixed treatment comparisons were also 
performed to allow the inference of indirect evidence (regimen comparisons without RCTs) and thus 
a network of evidence [24].  
The efficacy of several regimens was established in trials against placebo or no treatment, including 6 
month and 12 month isoniazid, 4 month rifampicin, and 3 month rifampicin and isoniazid. No trial 
determined the efficacy and safety of a 3-month regimen of weekly rifapentine plus isoniazid 
compared to placebo or no treatment, because this regimen was introduced at a time when 
conducting placebo controlled trials for LTBI was not considered ethically acceptable.   
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The main analysis considered studies that compared the above regimens against 6-month isoniazid 
(taken as reference) for efficacy and heptotoxicity (Table 3). In general, these comparisons did not 
show superiority of efficacy of one regimen over any other. However, in terms of safety, a 3–4 month 
rifampicin regimen and a 3 month weekly rifapentine plus isoniazid regimen had fewer hepatotoxicity 
events compared to the 6 month and 9 month isoniazid regimen, respectively.  In the absence of any 
direct comparison of efficacy of 6 and 9 month isoniazid, the equivalence of these two regimens was 
based on re-analysis of the United States Public Health Service (USPHS) trials conducted in the 1950s 
and 1960s that concluded that optimal protection from isoniazid appears to be obtained by nine 
months [25]. Pyrazinamide-containing regimens were evaluated in the analysis,  but were not 
considered for recommendation because of high documented toxicity [3, 26]. 
Based on these findings the following treatment options were recommended for the treatment of 
LTBI: 6 month isoniazid, or 9 month isoniazid, or 3 month regimen of weekly rifapentine plus isoniazid, 
or 3–4 months isoniazid plus rifampicin, or 3–4 months rifampicin alone. (Strong recommendation, 
moderate to high quality of evidence)  
Preventive treatment for contacts of MDR-TB cases 
The seventh systematic review was conducted to define the effectiveness of anti-TB drugs in 
preventing active TB in contacts of multidrug-resistant (MDR)-TB patients. Four studies were included 
for the analysis; all were cohort studies of which one [27] was a prospective study exclusively involving 
children below 5 years of age while the others were retrospective studies involving both adults and 
children [28-30]. For the final analysis, one study was excluded for its small sample size [29] while two 
other studies were excluded because all or the majority of MDR-TB contacts received preventive 
treatment with isoniazid [28, 30]. Therefore, the quality of evidence was determined using only one 
comparison study which used a tailored treatment regimen taking into account the resistance pattern 
of the index case among childhood contacts [27]. In this single study two of 41 children receiving 
tailored preventive therapy developed TB (confirmed and probable TB) compared to 13 of 64 children 
not receiving preventive treatment (OR=0.2, 95% CI: 0.04–0.94).  
There is thus sparse evidence on the effectiveness and safety of using anti-TB drugs to prevent active 
TB among adult and childhood contacts of MDR-TB cases. Furthermore, determination of the drug 
susceptibility profile for drugs to be used as preventive treatment for MDR contacts poses both 
technical and logistic challenges and may lead to drug-related harms, which would necessitate 
additional resources for close monitoring which has resource implications[31].  The Panel noted the 
serious limitations of evidence to draw any recommendations on MDR-TB preventive therapy as a 
public health measure and concluded that the management of contacts of MDR-TB patients needs to 
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be guided by a comprehensive clinical risk assessment considering the balance between risk and 
benefits for the individual. Based on the available evidence and the probability of increased likelihood 
to develop active TB disease following recent infection, strict clinical observation and close monitoring 
for the development of active TB disease for at least two years is preferred over the provision of 
preventive treatment for contacts of MDR-TB cases.  
 
Adverse event monitoring 
Drug-specific adverse reactions can occur with individuals who receive treatment for LTBI who are 
usually in good condition and not sick, making it more important to minimize risks of drug-induced 
harms during treatment. Adverse drug reactions in persons who take isoniazid include asymptomatic 
elevation of serum liver enzyme concentrations, peripheral neuropathy and hepatotoxicity. Rifampicin 
and rifapentine related adverse reactions include cutaneous reactions, hypersensitivity or flu-like 
reactions, gastrointestinal intolerance and hepatotoxicity. While most adverse drug reactions are 
minor and occur rarely, particular attention should be paid to prevent drug-induced hepatotoxicity.  
The eighth systematic review was conducted to assess the best way to monitor and manage 
hepatotoxicity and other adverse drug reactions and no studies were identified [32]. A review of 
national guidelines [33-37] instead showed consistent recommendations based on expert opinion, 
which were useful to inform the judgment of the Panel.  
Based on these observations, the Panel underlined the importance of routine regular clinical 
monitoring of individuals receiving treatment for LTBI through a monthly visit to health-care providers. 
The prescribing health-care provider should explain the disease process and the rationale of treatment 
and emphasize the importance of completing it. Those receiving treatment should be educated to 
contact their health-care providers should they develop symptoms such as anorexia, paraesthesiae, 
nausea, vomiting, abdominal discomfort, persistent fatigue or weakness, dark-coloured urine, pale 
stools or jaundice. Whenever a health-care provider cannot be consulted at the onset of these 
symptoms, treatment should be stopped immediately.  
The Panel noted that there was insufficient evidence to support baseline laboratory testing for 
measurements of serum aspartate aminotransferase, alanine aminotransferase and bilirubin. 
However, the Panel strongly encouraged baseline laboratory testing for individuals with any of the 
following risk factors: history of liver disease; regular use of alcohol; chronic liver disease; HIV infection; 
age more than 35 years; and pregnancy or the immediate postpartum period (i.e., within three months 
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of delivery). For individuals with abnormal baseline test results routine periodic laboratory testing 
should be done.  
 
Risk of drug resistance following LTBI treatment 
The ninth systematic review was conducted to determine whether LTBI treatment leads to significant 
development of resistance. The systematic review considered the following treatment regimens:  
Isoniazid for 6 to 12-month duration: An update of a previous systematic review was done [38]. 
Thirteen studies comparing 6 to 12-month isoniazid preventive therapy versus no treatment or 
placebo were included in the systematic review (seven involving HIV uninfected populations). There 
was no difference in the incidence risk of isoniazid-resistant TB (risk ratio = 1.45 (95% CI: 0.85–2.47)). 
There was little evidence of heterogeneity (p=0.923) and the risk ratio for HIV-uninfected and HIV-
infected populations were comparable.  
Rifamycin-containing regimens: Five studies were included in the comparison of rifamycin resistance 
in individuals treated with a rifamycin-containing regimen versus a regimen not containing rifamycin. 
There were very few cases of rifamycin resistance, a total of six (0.1%) cases in 5,790 individuals 
receiving LTBI treatment with a rifamycin and five (0.09%) cases in the 5,537 individuals in the control 
group with a relative risk of 1.12 (95% CI: 0.41–3.08). The quality of the evidence was very low.  
The Panel concluded that the available evidence showed no significant association between anti-TB 
drug resistance and the use of isoniazid and/or rifamycins for LTBI. However, the Panel emphasized 
the importance of establishing national TB drug resistance surveillance systems in countries 
implementing systematic testing and treatment for LTBI.  
 
Adherence and completion of preventive treatment 
Adherence to the full course and completion of LTBI treatment are important determinants of clinical 
benefit to the individual as well as to the success of the programme.  
Four systematic reviews (10-13th) were conducted to describe initiation and completion rates of LTBI 
treatment; to define determinants of initiation, adherence and completion rates of LTBI treatment; to 
assess interventions that are effective to improve those rates; and to assess if the duration of 
protection from LTBI treatment will be a barrier to implementation of LTBI treatment. All four reviews 
focused on prospective studies. 
16 
 
Completion rates were shown to vary greatly across risk groups ranging from 6% to 94%. In general, 
completion rates were lower among prisoners and immigrants compared with people living with HIV 
and contacts, and were inversely proportional related to the duration of treatment.  
Determinants of treatment initiation, adherence and completion identified in the systematic review 
were: (i) adverse drug reactions, (ii) longer duration of treatment, (iii) legal status among immigrants, 
(iv) long distance from health facility, (v) history of incarceration, (vi) absence of perception of risk, 
(vii) presence of stigma, (viii) alcohol and drug use, (ix) unemployment, and (x) time lag between 
diagnosis and treatment.  
Evidence on the efficacy of interventions to improve treatment adherence and completion showed 
that shorter treatment duration was significantly associated with increased adherence [39-41]. There 
is contradictory evidence on the role of monetary incentives to improve treatment completion rates, 
with randomized trials showing benefit of incentives (either monetary or methadone) on treatment 
completion rates among illicit drug users [42, 43], and other randomized trials among the homeless 
[44] and prisoners [45] not showing any significant impact. Significant increases in completion rates 
were demonstrated with peer-support and coaching among adolescents and adults[46-48]; nurse case 
management among the homeless [49]; cultural case management among immigrants [50]; and 
educational interventions among inmates [45]. No studies were found on the question whether the 
duration of protection from LTBI treatment will be a barrier to implementation of LTBI treatment. 
It was noted that the available evidence is heterogeneous and inconclusive to be able to recommend 
the best interventions to improve treatment adherence and completion. However, the Panel 
underlined the importance of designing flexible interventions that are tailored to respond to the local 
context and needs of the population to ensure acceptable initiation of, adherence to and completion 
of LTBI treatment as part of the public health approach.  
 
Cost effectiveness 
The fourteenth systematic review was conducted to critically appraise and summarize current 
evidence on the cost-benefit and cost-effectiveness associated with screening for and treatment of 
LTBI. Studies that evaluated costs and outcomes of any screening strategy and any drug regimen for 
LTBI compared to no intervention in any setting and population group were selected. The outcomes 
considered were incremental cost per quality-adjusted life year or life year gained, and incremental 
cost per TB case averted. Thirty nine articles were included and the majority of articles (82%) reported 
on analyses conducted in upper middle-income countries with TB incidence less than 100 per 100,000 
population. 
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Cost inputs (adjusted for currency and inflation to US$ value as of 2012), varied widely among studies. 
For example, the cost of testing for LTBI using TST varied from US$ 10.9 in a study from Italy[51] to an 
average of US$ 31.5 in studies from the United Kingdom[52]; similarly, detecting LTBI using an IGRA 
test varied from US$ 22.5 in a study from Mexico[53] to an average of US$ 97.1 in studies from the UK 
[52, 54]. Wide variations were also observed for the cost of screening eligible candidates for latent TB 
treatment and the overall cost. For example, the costs of monitoring adverse drug reactions (including 
liver function tests and clinical monitoring) ranged from US$ 8.3[55]  to US$ 687.3[56]. The average 
cost of treating LTBI (including cost of drugs and monitoring) ranged from US$ 381.9 in Italy[51] to 
US$ 1 129.9 in the UK[52].  
 
Studies showed that LTBI testing and treating of immigrants from high (between 120–150 per 100,000 
population) to low TB incidence countries may result in savings for the health-care system or have a 
favourable incremental cost-effectiveness ratio[52, 54, 57-61].  Similar results were found in studies 
among people living with HIV[51, 55, 60, 62] and contacts of patients with active TB[52, 61, 63-66]. 
However, a marked variability across studies in the economic inputs, in epidemiologic and TB natural 
history parameters, as well as in assumptions on the effectiveness of preventive treatment made the 
extrapolation of the results from one setting to another problematic. 
 
Discussion 
The main principle guiding testing and treatment for LTBI is that benefit outweighs the risk to the 
individual. The decision of national TB programmes and other stakeholders about the priority risk 
groups for programmatic management of LTBI needs to consider the local epidemiology of TB, and 
availability and efficient use of resources. Cost-effectiveness analyses based on rigorous empirical data 
are scarce. However, prioritizing high-risk groups, such as people living with HIV, adult and child 
contacts of pulmonary TB cases, as well as immigrants from high to low TB burden countries, for latent 
TB testing and treatment has the potential to yield savings for the health care system. The value of 
earlier antiretroviral therapy for the prevention of TB among people living with HIV is enormous [67]. 
Therefore, HIV testing should be incorporated into the clinical evaluation of LTBI treatment candidates 
based on national policies, and local epidemiology of HIV.   
The comparative analysis between TST and IGRA in the head-to-head studies showed no evidence that 
one test should be preferred over the other to assess progression to TB disease. Given the low positive 
predictive values for TB disease progression for both TST and IGRAs new diagnostic methods need to 
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be developed and evaluated. The resource requirements for choosing the test could vary and the 
decision needs to consider several factors, including the structure of the health system, feasibility of 
implementation, infrastructure requirements and Bacillus Calmette–Guérin (BCG) vaccination 
coverage and practice.  
The Panel agreed on the equivalence of 6 month isoniazid, 9 month isoniazid, 3 month weekly 
rifapentine plus isoniazid, 3–4 month isoniazid plus rifampicin and 3–4 month rifampicin alone. 
However, the Panel agreed that shorter duration regimens are preferred over longer duration 
regimens from the perspective of individuals receiving treatment, clinicians providing the treatment, 
and programme managers, and concluded that the 3 month regimen of weekly rifapentine plus 
isoniazid may have possible advantages over the other regimens. Similarly, the Panel agreed that 6 
month isoniazid is preferred over 9 month isoniazid due to resource requirements, feasibility and 
acceptability by patients. The Panel noted the reported positive acceptability of rifampicin- and 
rifapentine-containing regimens by individuals receiving treatment, and further concluded that 
rifampicin (3–4 months isoniazid plus rifampicin and 4-month rifampicin only) and isoniazid (6 and 9 
month) containing regimens could be self-administered by individuals receiving treatment. 
Rifampicin- and rifapentine-containing regimens should be prescribed with caution to people living 
with HIV who are on antiretroviral treatment due to potential drug-to-drug interactions. National 
programmes need to decide upon the treatment options to be offered in their country, taking into 
consideration their resource capacity and national and local context.  
 In addition to the general ethical considerations in TB programmes [68], LTBI testing and treatment 
raises a range of ethical issues [69] that need to be addressed through appropriate national policies 
and practices.  Policies should be evaluated under an ethical perspective after implementation, both 
to consider possible unexpected impact and to ensure that the evidence on which they are based 
remains current and relevant [70].  
The introduction of management of LTBI as a public health intervention will require the 
documentation of treated individuals through functional and routine monitoring and evaluation 
systems that are aligned with general national systems. Appropriate recording and reporting tools 
need to be developed, and standardized indicators established to regularly inform decision making. In 
some instances, these may require changes in the national legal and policy framework that have to be 
addressed according to the local and national context. Key indicators to be considered for the 
monitoring and evaluation system include: coverage of LTBI testing; treatment initiation and 
completion; the development of active TB during and after the completion of treatment for latent TB, 
monitoring of drug resistance, as well as reasons for not initiating and completing LTBI treatment. 
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Additionally, programme monitoring is needed to evaluate quality, programme effectiveness and 
impact. Nationally standardized indicators and data capturing mechanisms using electronic system 
and digital technology are also required.  
National TB programmes or their equivalents need to pursue multi-sectoral engagement and create a 
conducive policy and programmatic environment, including the development of national and local 
policies and standard operating procedures to facilitate the implementation of the recommendations 
in these guidelines. This could include promoting universal health coverage and prioritizing the risk 
groups based on the epidemiology of TB, as well as establishing robust health infrastructure and 
programmatic management. The planning of programmatic LTBI management should  be integrated 
with planning of systematic screening for active TB in high risk groups[71]. Dedicated resources will 
need to be allocated, including for human resource development and service delivery.  
The review of the evidence for formulating these recommendations exposed a number of gaps to 
better understand, diagnose and treat LTBI (see Box 2). It is imperative that donors and the scientific 
research community respond to these gaps in order to update the guidelines and optimize programme 
implementation. Such research should involve innovative synergies between the public and private 
sectors in order to overcome market shortcomings [3]. 
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Figure 1. Schematic approach for programmatic management of LTBI 
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Table 1: Primary target countries for the guidelines on LTBI management* 
EURO AMRO WPRO EMRO SEARO&AFRO 
Albania Antigua and Barbuda American Samoa Bahrain Mauritius 
Andorra Argentina Australia Iran (Islamic Republic 
of) 
Seychelles 
Austria Aruba Brunei Darussalam Iraq Maldives 
Azerbaijan Bahamas China Jordan Algeria 
Belarus Barbados China, Hong Kong SAR Kuwait  
Belgium Belize China, Macao SAR Lebanon  
Bosnia and 
Herzegovina 
Bermuda Fiji Libya  
Bulgaria Brazil French Polynesia Oman  
Croatia Canada Guam Qatar  
Cyprus Cayman Islands Japan Saudi Arabia  
Czech Republic Chile Korea, Republic of Tunisia  
Denmark Colombia Malaysia United Arab Emirates  
Estonia Costa Rica New Caledonia   
Finland Cuba New Zealand   
France Curaçao North Mariana Islands   
Germany Dominica Palau   
Greece Dominican Republic Singapore   
Hungary Ecuador Tonga   
Iceland Grenada    
Ireland Jamaica    
Israel Mexico    
Italy Panama    
Latvia Puerto Rico    
Lithuania St. Kitts and Nevis    
Luxembourg Saint Lucia    
Malta Saint Vincent and the 
Grenadines 
   
Monaco Sint Maarten    
Montenegro Suriname    
Netherlands Trinidad and Tobago    
Norway Turks and Caicos 
Islands 
   
Poland Uruguay    
Portugal US Virgin Islands    
Romania Venezuela (Bolivarian 
Republic of) 
   
Russian Federation United States of 
America 
   
San Marino     
Serbia     
Slovakia     
Slovenia     
Spain     
Sweden     
Switzerland     
The former Yugoslav 
Republic of Macedonia 
    
Turkey     
Turkmenistan     
United Kingdom     
*High income and upper-middle income countries according to World Bank income classification (2013) with annual TB incidence of less 
than 100 cases per 100 000 population (2013). 
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Box 1: Recommendations of the guidelines in high and upper-middle income countries with a 
TB incidence less than  100 per 100,000 population per year 
 Systematic testing and treatment of latent tuberculosis infection (LTBI) should be performed in people 
living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis 
factor (TNF) treatment, patients receiving dialysis, patients preparing for organ or haematologic 
transplantation, and patients with silicosis. Either interferon-gamma release assays (IGRA) or Mantoux 
tuberculin skin test (TST) should be used to test for LTBI. (Strong recommendation, low to very low quality 
of evidence) 
  Systematic testing and treatment of LTBI should be considered for prisoners, health-care workers, 
immigrants from high TB burden countries, homeless persons and illicit drug users. Either IGRA or TST 
should be used to test for LTBI. (Conditional recommendation, low to very low quality of evidence) 
 Systematic testing for LTBI is not recommended in people with diabetes, people with harmful alcohol use, 
tobacco smokers, and underweight people provided they are not already included in the above 
recommendations. (Conditional recommendation, very low quality of evidence) 
 Individuals should be asked about symptoms of TB before being tested for LTBI. Chest radiography can be 
done if efforts are intended also for active TB case finding. Individuals with TB symptoms or any 
radiological abnormality should be investigated further for active TB and other conditions. (Strong 
recommendation, low quality of evidence) 
 Either TST or IGRA can be used to test for LTBI in high-income and upper middle-income countries with 
estimated TB incidence less than 100 per 100 000 (Strong recommendation, low quality of evidence). IGRA 
should not replace TST in low-income and other middle-income countries. (Strong recommendation, very 
low quality of evidence) 
 Treatment options recommended for LTBI include: 6-month daily isoniazid, or 9 month daily isoniazid, or 3 
month weekly rifapentine plus isoniazid, or 3–4 month daily isoniazid plus rifampicin, or 3–4 month daily 
rifampicin alone. (Strong recommendation, moderate to high quality of evidence 
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Table 2. Performance of different screening strategies to rule out active TB before LTBI treatment 
based on a hypothetical cohort population of 1000 at a baseline TB prevalence of 0.5%[21]. 
Screening strategy Sensitivity 
(%) 
Specificity 
(%) 
Negative 
Predictive 
Value 
 (%) 
False negatives 
at screening (n) 
False positives 
at screening (n) 
Cough for more than 
2-3 weeks alone 
35 95 99.6 3 53 
Presence of cough for 
more than 2-3 weeks 
followed by chest 
radiography (CXR) 
 90 56 99.7 3 23 
Any tuberculosis (TB) 
symptom alone* 
77 68 99.8 1 321 
Presence of any TB 
symptom followed by 
CXR 
90 56 99.8 1 141 
TB specific 
abnormality on CXR 
87 89 99.9 0.6 105 
Any abnormality on 
CXR 
98 75 99.9 0.1 244 
Any abnormality on 
CXR plus presence of 
any TB symptom 
100 61 100 0 385 
*Any TB symptom includes: any one of cough, haemoptysis, fever, night sweats, weight loss, 
chest pain, shortness of breath and fatigue   
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Table 3: Standard random effects meta-analysis comparison of efficacy and hepatotoxicity among 
various treatment regimens for treatment of latent tuberculosis infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*exclusively among people living with HIV. 
 
Comparator Intervention Development of incident TB 
Odds ratio (OR) (95% CI) 
Hepatotoxicity 
Odds ratio (OR) (95% CI) 
Placebo Isoniazid 6 months 0.61 (0.48–0.77) 0.99 (0.42–2.32) 
Placebo Isoniazid 12–72 months 0.53 (0.41–0.69) 0.59 (0.23–1.55) 
Placebo Rifampicin 3–4 months 0.48 (0.26–0.87) - 
Placebo Rifampicin and isoniazid 3–
4 months 
0.52 (0.33–0.84) - 
Isoniazid 6 
month 
Rifampicin 3–4 months 0.78 (0.41–1.46) 0.03 (0.00–0.48) 
Isoniazid 6 
month 
Rifampicin and isoniazid 3–
4 months 
0.89 (0.65–1.23) 0.89 (0.52–1.55) 
Isoniazid 6 
month 
3 month weekly 
rifapentine plus isoniazid* 
1.09 (0.60–1.99) 1.00 (0.50–1.99) 
Isoniazid 9 
month 
3 month weekly 
rifapentine plus isoniazid 
0.44 (0.18–1.07) 0.16 (0.10–0.27) 
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Box 2: Priority research gaps identified for revision of the guidelines 
 Measurement of the risk of progression from LTBI to active disease in a number 
of risk groups 
 Direct measurement of TB incidence in cohort studies of risk groups compared 
to general population (e.g. TST positive cohort in a risk group versus TST positive 
cohort in the general population) or through alternative methods (such as the 
use of genotyping to measure the risk of reactivation in comparison studies). 
 Generating evidence on the benefits and harms of systematic treatment of LTBI 
in all risk groups and particularly the following groups: diabetic patients, people 
with harmful alcohol use, tobacco smokers, underweight people, persons with 
silica exposure, patients receiving steroid treatment, patients with 
rheumatologic conditions, indigenous populations and cancer patients. 
 Social adverse events of LTBI treatment by risk group treated 
 Operational and clinical studies to identify undiagnosed active TB before LTBI 
treatment initiation 
 Diagnostic performance of the algorithm proposed in these guidelines as well as 
development and evaluation of new algorithms tailored to the needs of specific 
risk groups  
 Prospective, randomized studies tailored to specific risk group to measure the 
incremental benefits of routine monitoring of liver enzymes over education and 
clinical observation alone in terms of preventing severe clinical adverse events.  
 Programme-based surveillance systems and clinical studies to monitor the risk of 
drug resistance following LTBI treatment. 
 Efficacy studies of currently recommended treatment options in areas of highly 
prevalent drug resistance 
 The effectiveness of context-specific interventions to enhance adherence and 
treatment completion tailored by risk groups 
 Direct measurement of cost-effectiveness in specific settings and risk 
populations  
 Adequately powered randomized controlled trials to define the benefits and 
harms of treatment of MDR-TB contacts. 
 Epidemiological studies to understand the burden of LTBI and inform the 
development of nationally and locally tailored interventions 
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